Ana Jaklenec's bio

Ana Jaklenec has over 10 years of experience in the area of bioengineering, materials science, micronutrient and vaccine stabilization and delivery. She is a Research Scientist and Co-Principal Investigator in the Langer Lab, at the Koch Institute for Integrative Cancer Research at MIT. She has written over 30 articles in high impact journals and has over 20 issued and pending patents worldwide.

Dr. Jaklenec holds a B.S. in Biomedical Engineering from Boston University and a Ph.D. in Biomedical Engineering from Brown University. Her postdoctoral training was with Institute Prof. Robert Langer and Prof. Daniel Anderson at MIT, where her research focused on drug delivery of biologics (among other projects). She is the recipient of the Ruth L. Kirschstein National Research Service Award (NRSA) from the National Institutes of Health (NIH). Dr. Jaklenec was elected to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows in 2022 for her work in controlled delivery of vaccines and heat-stable micronutrients for global health that can change the world. She was also elected to the Controlled Release Society (CRS) College of Fellows in 2022 for her research at the interface of engineering and immunology that utilizes precise fabrication and design of materials at the nano- and micro-scale for use in controlled drug delivery for global health.Additionally, she has supervised over 50 pre- and post-doctoral students, many of whom are currently faculty at universities in the US and abroad.

Her research at MIT is at the interface of engineering and immunology with a focus on global health. Her major focus is the study and development of polymers to deliver liable drugs, particularly vaccines, DNA vectors and mRNAs, in stable form for prolonged periods of time with unique kinetics. Her lab is currently working in the following areas: developing single-injection self-boosting vaccines; nanocarrier-based vaccine approaches targeting protective memory responses after parenteral immunization; 3D printed on-demand microneedle vaccines; developing on patient medical records using invisible dyes; creating long-term drug delivery systems for cancer immunotherapy; developing heat stable polymer-based carriers for oral delivery of micronutrients and probiotics.

She is an active member of the Biomedical Engineering Society (BMES), Controlled Release Society (CRS), and the Society for Biomaterials (SFB) and the currently serves as the Chair of the CRS Oral Drug Delivery Focus Group and the Secretary/Treasurer of the SFB Drug Delivery SIG.

See Ana's publications, also on Google Scholar.